Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: Epitope mapping and cytotoxicity on retinal cells

Citation
G. Adamus et al., Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: Epitope mapping and cytotoxicity on retinal cells, J AUTOIMMUN, 11(6), 1998, pp. 671-677
Citations number
23
Categorie Soggetti
Immunology
Journal title
JOURNAL OF AUTOIMMUNITY
ISSN journal
08968411 → ACNP
Volume
11
Issue
6
Year of publication
1998
Pages
671 - 677
Database
ISI
SICI code
0896-8411(199812)11:6<671:AAICRE>2.0.ZU;2-9
Abstract
Patients with cancer-associated retinopathy syndrome (CAR), a progressive b linding disease related to retinal degeneration and systemic tumor outside the eye, develop autoantibodies against alpha-enolase. A small percentage o f healthy subjects without evident tumor or visual symptoms also possess au toantibody against enolase. In these studies we examined the fine specifici ty of anti-enolase antibodies derived from patients with CAR and healthy in dividuals, using synthetic peptides covering the entire sequence of human a lpha-enolase. Epitope mapping revealed that three binding regions of enolas e within the residues 31-38 (FRAAVPSG), 176-183 (ANFREAMR), and 421-428 (AK FAGRNF) were common for all autoantibodies tested. However, pathogenic sera recognized an additional unique region, the sequence 56-63 (RYMGKGVS). The re were also differences in in vitro cytotoxic activities on E1A.NR3 retina l cells and cell-death promoting activities between anti-enolase antibodies of healthy and CAR affected individuals. These studies showed that anti-en olase antibodies from patients with CAR were able to induce apoptotic cell death in E1A.NR3 retinal cells and provided a potential mechanism for retin al degeneration in humans. (C) 1998 Academic Press.